To compare the efficacy of emollient versus topical luliconazole (azole) in the maintenance of remission of recurrent dermatophytosis after adequate systemic treatment.
Phase 3
- Conditions
- Health Condition 1: L088- Other specified local infections of the skin and subcutaneous tissue
- Registration Number
- CTRI/2023/01/049161
- Lead Sponsor
- AIIMS Rajkot
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Closed to Recruitment of Participants
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
1.Males and females >18 years of age.
2.Patients having tinea infection for more than 6 months.
3.Providing signed consent forms after understanding the written contents outlining the requirements of participating in the study.
Exclusion Criteria
1.Pregnant or breastfeeding woman.
2.Patients suffering from diseases where immunosuppressants are indicated like autoimmune conditions.
3.Patients with history of heart disease especially chronic heart failure
4.Patients with concomitant other skin diseases.
5.Patients with tinea capitis.
6.Patients with abnormal liver function test
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.To assess the efficacy of emollient in the remission maintenance of recurrent dermatophytosis.(Using Physician Global Assessment score and Patient Global Assessment of Disease Status) <br/ ><br>2.To compare the efficacy of emollient with topical luliconazole use in the remission of tinea infection. <br/ ><br>We tend to monitor remission of disease in the form of new tinea lesions through the validated scores.Timepoint: 6 weeks <br/ ><br>The assessment of data in the follow up period will be assessed with the validated scoring system both for the physician and patient. Data collected will be statistically assessed using independent â??Tâ?? test.
- Secondary Outcome Measures
Name Time Method To evaluate the effectiveness of extended use of topical luliconazole for maintenance of remission in recurrent dermatophytosis patients. <br/ ><br>We tend to monitor remission of disease in the form of new tinea lesions through the validated scores. <br/ ><br> <br/ ><br>Timepoint: 18 weeks <br/ ><br> <br/ ><br>